Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells

Zhe Chang1,7, Zhongkui Li1, Xiaoyang Wang9, Ya’an Kang2, Yuhui Yuan1, Jiangong Niu4, Huamin Wang3, Deyali Chatterjee2, Jason B. Fleming2, Min Li8, James L. Abbruzzese5, and Paul J. Chiao1,2,6,7

Abstract

Purpose: The most common genetic lesions in pancreatic ductal adenocarcinoma (PDAC) have been identified. However, significant gaps still exist in our understanding of how such genetic alterations act in concert to induce PDAC development. In this study, we investigated the mechanism of tumorigenic transformation in the immortalized human pancreatic ductal epithelial (HPDE) cell line by sequentially introducing PDAC signature alterations into this cell line.

Experimental Design: The phenotype for stable expression of mutant K-ras, Her2, p16/p14shRNA, and Smad4shRNA in HPDE cells was examined by assays for cell proliferation, migration, invasion, soft agar, and orthotopic tumorigenesis. The mechanisms of tumorigenic transformation were further explored by gene expression profiling and pathway analyses.

Results: The transformed cells exhibited enhanced proliferation, migration, and invasion, displayed anchorage-independent growth in soft agar, and grew orthotopic tumors with some histopathologic features of PDAC. We found that Smad4 played key roles in the tumorigenic transformation of HPDE cells. We further found that MDM2 and Bmi-1 were overexpressed in the tumorigenic HPDE cells and that Bmi-1 overexpression was regulated by Smad4. Ingenuity Pathway Analysis software analysis of microarray data revealed that dysregulation of integrin-linked kinase signaling and the cell cycle were the most significant changes involved in tumorigenic transformation. Altogether, this cell culture model closely recapitulated human pancreatic carcinogenesis from gene lesions, activation of specific signaling pathways, and some histopathologic features.

Conclusion: The combination of activated K-ras and Her2 with inactivated p16/p14 and Smad4 was sufficient and essential to transform HPDE cells, thus revealing the potential tumorigenic mechanism.

Introduction

The development of PDAC is a multistep process resulting from the accumulation of genetic lesions in normal cells. The most common genetic alteration in PDAC, and one of the earliest identified, is the K-ras mutation (90%), which plays a critical initiating role in this disease (1–4). Her2 overexpression (70%) is frequently found in well-differentiated PDACs as well as in early-stage precancerous lesions and correlates with shorter survival and worse prognosis (5, 6). Inactivation of p16 in PDAC occurs through homozygous deletion (40%), an intragenic mutation coupled with loss of the second allele (40%), and promoter hypermethylation (15%), resulting in increased phosphorylation of the Rb and cell-cycle progression through the G1 phase into the S-phase (7, 8). p53 inactivation (50%–75%) and p14 deletion (40%) are also frequently found (9, 10). Deletion of p14 and p53 mutation coexist in approximately 40% of PDAC cases (1, 9). Inactivation of Smad4 has been found in approximately 55% of the PDAC cases (10) and is detected only in late-stage pancreatic intraepithelial neoplasia (PanIN) and PDAC, indicating that loss of Smad4 is a late genetic event in PDAC (11). Studies based on PDAC mouse models have revealed the role of several of the most common genetic mutations in PDAC, including Smad4 inactivation, as key steps in the progression of PDAC (12–15). However, the role of, and the mechanisms associated with, activation of K-ras and Her2...
Translational Relevance

K-ras is the most frequently identified genetic alteration in the pancreatic ductal adenocarcinoma (PDAC). Inhibiting mutated K-ras directly with small-molecule inhibitors has thus far been unsuccessful; therefore, approaches are being made to identify potential therapeutic targets based on the understanding of the mechanisms through which the alterations act in concert to induce PDAC. Our novel in vitro experimental cell transformation model system with genetically defined alterations would provide a necessary tool for studying the molecular mechanism of disease progression and the specific altered oncogenic signaling pathways in human PDAC. This cell model could also be used to assess the efficacy of new therapeutic agents for PDAC induced with signature mutations without the confounding interference of other unknown genetic alterations, as the orthotopic tumor derived from these cells recapitulates some of the PDAC histopathologic features.

and inactivation of p16/p14 and Smad4 in human pancreatic carcinogenesis are still not well understood.

The cell culture model remains an important complement to the mouse model and is an important tool in the study of human cancer, but few human pancreatic cell culture transformation models have been reported to date (16). Qian and colleagues first showed that expression of mutant K-RasG12V in the human papillomavirus (HPV)-16 E6E7 immortalized human pancreatic ductal epithelial (HPDE) cell line and induced only weak tumorgenesis in the orthotopic mouse model, with poorly differentiated tumor formation in 2 of 5 severe combined immunodeficient (SCID) mice (17). The study in our laboratory showed that mutant K-ras alone failed to induce tumor growth in nonobese diabetic (NOD)/SCID mice (J. Niu, unpublished data), suggesting that K-ras alone may not be sufficient for the development of PDAC and that additional genetic alterations are required to induce fully malignant transformation of the HPDE cell line. Another recent study described a complete malignant transformation cell model using an hTERT-immortalized normal human pancreatic ductal nestin–expressing cell line through sequential introduction of E6E7, K-rasG12D, and the SV40 small t antigen into this cell line (18). These cells become transformed as they formed colonies in soft agar and developed into subcutaneous tumors in nude mice. However, in this model, the frequently found mutations in human PDAC were not used to cooperate with K-ras to induce tumorigenic transformation.

In this study, we investigated the mechanisms of tumorigenic transformation by sequential introduction of activated K-ras and Her2 and p16/p14 and Smad4shRNA to the HPV E6E7 oncprotein–immortalized HPDE cells. Analysis of gene expression showed that activation of several signaling pathways, such as integrin-linked kinase (ILK), cell cycle, and Smad4-regulated expression of Bmi-1, is significantly involved in tumorigenic transformation.

Materials and Methods

Cell lines and cell culture

The human pancreatic ductal epithelial cell line HPDE/ E6E7 was obtained from Dr. Ming-Sound Tsao (Ontario Cancer Institute at Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada). HPDE/E6E7 cells were cultured at 37°C in 5% CO2 in keratinocyte serum-free medium (Invitrogen Life Technologies, Inc.) supplemented with 50 μg/mL bovine pituitary extract (Invitrogen) and 5.0 ng/mL recombinant human EGF (Invitrogen). K-ras–expressing HPDE cell lines were cultured in a 1:1 mixture of complete keratinocyte serum-free medium and complete Dulbecco's modified Eagle's medium (Hyclone Laboratories Inc.) with 5% FBS. The 293T cell line and human pancreatic cancer cell lines were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS at 37°C in 5% CO2.

Plasmid construction, transfection, retroviral or lentiviral production, infection, and establishment of stable cell lines

Detailed methods can be found in the Supplementary Materials and Methods.

Western blot analysis

Cells were lysed in radioimmunoprecipitation assay (RIPA) protein lysis buffer. A total of 50 μg of protein extracts were analyzed by Western blot analysis as described previously (19).

Ras activity assay

The activity of the Ras protein was assayed by using the Ras assay reagent (Upstate Biotechnology Inc.) according to the manufacturer's instructions and were conducted as described previously (17).

Histological and immunohistochemical analysis

Hematoxylin and eosin (H&E) and immunohistochemical analyses were conducted according to standard procedures. The H&E and immunohistochemical slides from mouse xenografts were reviewed by a pathologist (H. Wang), who classified the tumor type and characterized the histologic features. A representative field was photographed and shown with use of an Olympus BX-51TF microscope.

Gene expression profiling, ingenuity, and signaling pathway analyses

DNA microarray experiments and statistical analyses were carried out by the Cancer Genomics Core Laboratory at the University of Texas MD Anderson Cancer Center (Houston, TX) with the Whole Human Genome Oligo Microarray from Agilent Technologies according to the manufacturer's instructions. The changes of signaling pathways and biologic functions were analyzed with use of
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, www.ingenuity.com; Ingenuity System Inc). Both core analysis and comparison analysis were conducted. The significance of the biologic functions and the canonical pathways was tested by the Fisher exact test on the basis of the number of genes analyzed that mapped to a biologic function and pathway in the IPA knowledge base. The results were shown by the $-\log (P\text{ value})$ of each pathway or biologic function mapped to a pathway or biologic function, respectively, in the IPA knowledge base.

**Statistical analyses**

All statistical analyses were conducted with use of SPSS or Excel software. The significance of the data was determined by the Student t-test and Fisher exact test. $P < 0.05$ was considered significant. For error bars in all experiments, SD was calculated from 3 independent experiments, and values represent mean ± SD.

**Results**

**Stable expression of mutant K-ras, Her2, p16/p14shRNA, and Smad4shRNA in the E6E7 immortalized HPDE cell line**

We sequentially introduced 5 of the most commonly identified genetic alterations in PDAC—activated K-ras and Her2 and inactivated p16 or p16/p14 and Smad4—by shRNA knockdown in HPDE cells via retroviral or lentiviral transduction based on the use of various drugs or GFP fluorescence–activated cell sorting to purify the antibiotic-resistant or GFP-positive cell population (Fig. 1A). The expression of K-rasG12A and K-rasG12B in HPDE cell lines induced increased Ras activity 1.8- to 2.2-fold and increased the RasG12 level compared with vector control cells in the Ras activity assay and Western blotting (Fig. 1B), suggesting a near endogenous level of K-ras expression in our HPDE cell culture–based model. However, the expression level of mutant K-ras in HPDE cells was lower than that in a panel of human PDAC cell lines (Supplementary Fig. S1A). Stable expression of Her2, p16/p14shRNA, and Smad4shRNA in HPDE/K-ras (HPDE/K-rasG12) cells was confirmed by Western blotting, which also was used to show overexpression of Her2 in transduced HPDE cells, at levels similar to those in several human PDAC cell lines (Supplementary Fig. S1B), as well as decreased expression of p16, p14, and Smad4 in these transduced cells (Fig. 1C). The reduction of p53 by HPV E6 oncoprotein–mediated degradation could not be determined as HPDE was established as a cell line by expression on E6E7 oncoproteins. The function of p53 was compromised in HPDE, as evidenced by its failure to induce p21WAF1 expression after γ-irradiation.

**Figure 1.** Stable expression of K-rasG12, Her2, p16/p14shRNA, and Smad4shRNA in HPDE/K-rasG12 cell lines. A, the strategy for introducing genetic alterations into HPDE cell lines. B, stable expression of K-RasG12A and 4B G12 in the HPDE cell lines. Stable K-rasG12 expression in the HPDE cells was identified by the Ras activity assay and the expression levels of RasG12 and total Ras by Western blot analysis. C, stable expression of the p16shRNA, p16/p14shRNA, Her2, and Smad4shRNA in HPDE/K-ras cell lines. The stable cell lines were identified by Western blot analysis of the expression of Her2, p16, p14, and Smad4. FACS, fluorescence-activated cell sorting.
The results suggested that p53 was inactivated, and this conclusion was consistent with that of Quin and colleagues, who found that p53 is not functional in the HPDE/E6E7 cell line (17). We thus successfully established stable cell lines with expression of mutant K-ras and Her2 and knockdown of p16INK4A/p14ARF and Smad4 tumor suppressor genes in immortalized HPDE cells.

Activation of K-ras and Her2 and inactivation of p16/p14 and Smad4 tumor suppressor genes induced increased cell migration and invasion

To determine whether activation of K-ras and Her2 and inactivation of p16/p14 and Smad4 induce cell migration and invasion in vitro, migration and Matrigel invasion assays were conducted. The results showed that cell lines HPDE/K-ras/Her2/p16p14shRNA, HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA, and most of HPDE cell lines with Smad4 silencing exhibited increased cell migration and invasion ability compared with other control cells (Supplementary Fig. S2; P < 0.05). Surprisingly, the HPDE/K-ras/p16shRNA cells exhibited increased cell migration and invasion compared with the control HPDE/K-ras cell line and HPDE/K-ras/p16shRNA/Smad4shRNA cells (Supplementary Fig. S2; P < 0.05). These results suggested that activation of K-ras and expression of Her2 and knocking down of p16/p14 or Smad4 initiated migration and invasion potential in HPDE cells before the emergence of the tumorigenic phenotype as observed in HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA.

Cell growth properties and anchorage-independent growth cell growth of HPDE cell lines with stable expression of mutant K-ras, Her2, p16/p14shRNA, and Smad4shRNA

Because unchecked cell growth is a hallmark of cancer, we examined the growth characteristics of these HPDE cells. The cell lines HPDE/K-ras/Her2/p16p14shRNA and HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA showed a significantly elevated cell growth rate and a higher percentage of cells in the S-phase in a cell-cycle analysis compared with other control cell lines (Fig. 2A, P < 0.05 on days 5 and 7; Fig. 2B). The HPDE/K-ras/p16p14shRNA/Smad4shRNA cell line also displayed a higher percentage of cells in the S-phase (26.3%) compared with its control cell lines (Fig. 2B). Knockdown of p16 and p14 simultaneously induced a higher cell proliferation rate than did knockdown of p16 alone, when comparing the HPDE/K-ras/p16p14shRNA cell line with the HPDE/K-ras/p16shRNA cell line, or comparing the HPDE/K-ras/p16p14shRNA/Smad4shRNA cell line with the HPDE/K-ras/p16shRNA/Smad4shRNA cell line (Fig. 2A; P < 0.05). Our results indicated that the loss of p14 and p16 simultaneously gives cells an additional growth advantage compared with the loss of p16 alone. These results suggest that p16/p14 suppresses mitogenic stimulation of K-ras and Her2-induced cell proliferation and that loss of p16/p14 releases the constraint on proliferation, thus inducing increased cell proliferation in HPDE cells. Together, our results suggested that HPDE cell lines with expression of mutant K-ras and Her2 and knockdown p16/p14 and Smad4, increased the ability for cell proliferation.

To investigate whether the HPDE cells had acquired the ability of anchorage-independent growth, one of hallmarks of in vitro cell transformation, we conducted soft agar assays to determine the transformation potential of mutant K-ras and Her2 and of knocked down p16/p14 and Smad4 in HPDE cells. The results showed that the 2 cell lines HPDE/K-ras/Her2/p16p14shRNA and HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA grew significantly more and larger colonies compared with all other control cell lines (Fig. 2C and D; P < 0.05). We also found that cell line HPDE/K-ras/p16p14shRNA/Smad4shRNA grew more colonies than did other control cell lines (Fig. 2C and D; P < 0.05). These results suggest that the combination of expressed mutant K-ras and Her2 and knocked down p16/p14 with or without knocked down Smad4 induced anchorage-independent growth in the soft agar assay and was sufficient to transform immortalized HPDE cells in vitro.

Activation of K-ras and Her2 and inactivation of p16/p14 and Smad4 in HPDE cell line induced tumorigenesis in orthotopic mouse model

The tumorigenic potential of HPDE cells in vivo was assessed by an orthotopic tumorigenesis assay in NOD/SCID mice. Only cells from cell line HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA formed tumors in 5 of 5 mice, as shown by in vivo bioluminescence imaging (Fig. 3A); when cells from other cell lines were injected into the mice, no tumors were found even after 6 months of observation (Supplementary Table S1). At 8 weeks after HPDE cell injection, mice started growing tumors and were euthanized at 12 to 20 weeks. Histologic analysis of these tumors revealed a moderately to poorly differentiated PDAC phenotype with a large area of undifferentiated carcinoma (Fig. 3B). Metastases to other organs such as liver or spleen were not observed in the mice either by gross inspection of the mouse organs or by H&E staining of sections from the liver, spleen, and abdominal cavity; local invasion to adjacent abdominal wall and skeletal muscle, however, was found on H&E staining. The tumors had large pleomorphic nuclei and prominent nucleoli and displayed several (3–7) mitotic figures per high-power field. As revealed by immunohistochemical analysis, the tumors expressed ductal cell marker cytokeratin-19 (CK-19) and the cell proliferation marker Ki-67 (Fig. 3B), and desmoplastic stroma was presented in some areas of the tumor masses, a hallmark feature of PDAC. These results suggested that our model mimicked the histologic features of tumors from cultured human PDAC cells.

We successfully isolated and cultured the tumor cell lines (HPDE/K-ras/Her2/p16p14 shRNA/Smad4shRNA T) from the orthotopically xenografted tumors. When reimplanted orthotopically into the pancreas of NOD/SCID mice, these cells formed tumors in all of the animals (3/3; Fig. 3C), and...
the latency of tumor development was also markedly reduced. In 40 days, huge tumors were observed in all mice. Histopathologic analysis of tumors also exhibited moderately to poorly differentiated PDAC, similar to the original xenograft tumor. To validate the gene expression in HPDE tumor cell lines, we carried out Western blotting and found that Her2 was overexpressed and that expression of p16, p14, and Smad4 was decreased in tumor cell lines (Fig. 3D). Thus our results confirmed the alterations of gene expression in the tumors.

Expression of cell proliferation–associated genes and activation of signaling pathway downstream of K-ras and Her2

As transformed cells exhibited increased cell proliferation, we examined whether the expression of cell proliferation–associated genes such as cyclins were changed in the transformed cells. We found that expression levels of cyclin D1 and cyclin B1, which are involved in G1–S and G2–M cell-cycle progression, respectively, were markedly elevated in the HPDE/K-ras/p16p14shRNA,
HPDE/K-ras/p16p14shRNA/Smad4shRNA, the HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA cell lines compared with other control cell lines (Fig. 4A). To determine the role of Smad4 in HPDE cell transformation, we examined the expression of c-myc and Id2 as the Smad4 downstream genes associated with cell proliferation and whether this expression was changed in those transformed cells. Our results revealed that the expression of c-myc and Id2 was significantly increased in the HPDE/K-ras/p16p14shRNA, HPDE/K-ras/p16p14shRNA/Smad4shRNA, the HPDE/K-ras/Her2/p16p14shRNA, and the HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA cell lines compared with their other control cell lines (Fig. 4A), indicating that Smad4 plays a role in the regulation of c-myc and Id2; knockdown of Smad4 increased the expression of c-myc and Id2 in the HPDE/K-ras cell line. However, in other HPDE cell lines, the increased c-myc and Id2 expression was not solely regulated by Smad4. These results suggest that increased expression of cell proliferation–associated gene cyclins c-myc and Id2 may be involved in enhanced cell proliferation and the transformation of HPDE cells.

To dissect the mechanism of transformation of HPDE cells and explore the pathways critical for the transformation, we first investigated the 3 most common downstream signaling pathways of K-ras and Her2: RAF/MEK/ERK, phosphoinositide-3 kinase (PI3K)/AKT, and RalGDS/Ral. We found that expression levels of the phosphorylated proteins of RAF, MEK, ERK, and p38, as well as the respective total protein levels of MEK, ERK, and p38, were enhanced in the cell lines HPDE/K-ras/p16p14shRNA and HPDE/K-ras/p16p14shRNA/Smad4shRNA, and HPDE/K-ras/Her2/p16p14shRNA and HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA compared with their other control cell lines (Fig. 4B). Activation of the ERK and p38 in transformed HPDE cells suggested that activation of K-ras and Her2 downstream effectors in the mitogen-activated protein kinase (MAPK) pathway may play a role in the malignant transformation of HPDE cells. We found weak AKT activity in cell lines HPDE/K-ras/Her2/p16p14shRNA and HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA, but higher AKT activity in the HPDE/K-ras/p16shRNA cell line than in all other cell lines (data not shown). There was no difference for RalA and RalB activity among the various cell lines (data not shown). These findings suggest that the downstream signaling pathways of K-ras and Her2, RAF/MEK/ERK and PI3K/AKT, are activated in various HPDE sublines.

Alterations of gene expression for transformation in microarray analysis
To better understand the molecular mechanisms of human pancreatic cell transformation and to gain further mechanistic insight into the detailed molecular alterations involved in the transformation, we conducted a microarray gene expression analysis. The top 10 most significantly upregulated and downregulated genes for cell line HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA versus cell line HPDE/K-ras/Her2/p16p14shRNA in microarray analysis
are shown in Supplementary Table S2A. We confirmed the elevated expression of oncogene MDM2 in transformed cell line HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA in cDNA microarray data by Western blotting (Fig. 5A). The results showed that the MDM2 protein was highly expressed in the cell lines with knockdown of p14 in the Western blot, thus confirming the previous finding of regulation of MDM2 by p14 (20), but the p53 level was not affected by MDM2 (Fig. 5A). Cell line HPDE/K-ras/p16shRNA/Smad4shRNA also had increased MDM2 expression (Fig. 5A). In addition, we found that MDM2 was overexpressed in 9 (75%) of 12 pancreatic cancer cell lines compared with levels in immortalized pancreatic cell lines (Fig. 5B). These results suggest that MDM2 may play a role in pancreatic cell transformation and tumorigenesis. To determine the mechanism by which MDM2 expression is elevated in HPDE cells with p14 knockdown and HPDE cells expressing 16shRNA/Smad4shRNA, we analyzed MDM2 mRNA expression levels and stability by quantitative PCR (qPCR) using the total RNA from various time points of actinomycin D–treated cells. Results showed that MDM2 mRNA stability was not altered in these cells but that the levels of MDM2 mRNA were increased in HPDE/K-ras/p16 shRNA, HPDE/K-ras/p14p16shRNA, and HPDE/K-ras/p16shRNA/Smad4shRNA (Fig. 5C and D). Our findings suggest that MDM2 expression is primarily regulated at transcription.

We found that Bmi-1, a putative polycomb oncogene, was overexpressed in HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA cells on microarray analysis. We found that knockdown of Smad4 enhanced expression of the Bmi-1 protein in HPDE cells (Fig. 5E). We also found that Bmi-1 was markedly overexpressed in 11 (85%) of 13 PDAC cell lines and in HPDE tumorigenic cell lines compared with the very low level in HPDE and HPDE/K-ras cell lines, respectively (Fig. 5F and G). Together, these results suggest that Smad4-regulated Bmi-1 may play an important role in the transformation of HPDE cells. To determine how Bmi-1 expression is upregulated by Smad4 knockdown, we analyzed Bmi-1 mRNA levels and stability by qPCR by using the total RNA from various time points of actinomycin D–treated cells. Our results show that Bmi-1 mRNA stability is not changed in these cells, but the levels of Bmi-1 mRNA are increased in HPDE cells with K-ras/p14p16shRNA and in HPDE/K-ras/Smad4shRNA cells (Fig. 5H and I), suggesting that Bmi-1 expression is mainly regulated at transcription. The other Smad4-regulated genes that we found and validated were bone morphogenetic protein 7 (BMP7) and growth factor receptor-bound protein 10 (GRB10; Supplementary Fig. S3). In K-ras and Her2-expressing cell lines, knockdown of Smad4 increased the expression of BMP7 (Supplementary Fig. S3A), and BMP7 was highly overexpressed in 9 (64%) of 14 pancreatic cancer cell lines compared with the lower level in the control HPDE cells (Supplementary Fig. S3B). The results showed that knockdown of Smad4 reduced the mRNA expression level of GRB10 genes on real-time PCR (RT-PCR) analysis (Supplementary Fig. S3C). GRB10 is an adapter protein that interacts with several mitogenic receptor tyrosine kinases, including the insulin and insulin-like growth factor-I receptor (21). Overexpression of some isoforms of GRB10...
inhibits tyrosine kinase activity and induces growth suppression (21). We thus confirmed the presence of several differentially expressed genes in the transformed cell lines compared with control cells.

**The alterations of signaling pathway for transformation**

To explore the signaling pathway alterations that are critical for the transformation of pancreatic ductal cells, we conducted an IPA signaling pathway analysis of microarray data. The most significant alterations of biologic functions for the HPDE/K-ras/Her2/p16p14shRNA/Smad4shRNA cells versus the HPDE/K-ras/Her2/p16p14shRNA cells were DNA replication, recombination, and repair, as well as cellular movement, death, growth, and proliferation (Fig. 6A). The most significant signaling pathway alterations were ILK signaling, cell cycle G2–M DNA damage checkpoint for cell line HPDE/K-ras/Her2/p16p14shRNA/
Smad4-shRNA versus HPDE/K-ras, and cell cycle G1–S checkpoint regulation for cell line HPDE/K-ras/Her2/p16-p14-shRNA/Smad4-shRNA versus HPDE/K-ras/Her2/p16-p14-shRNA (Fig. 6B). In conclusion, the results from IPA signaling pathways analysis suggested that abnormal ILK signaling and cell-cycle dysregulation were most significantly associated with transformation of human pancreatic ductal epithelial cells.

Discussion

In this study, we showed the mechanism of tumorigenic transformation of HPDE cells by sequential introduction of activated K-ras and Her2 with p16/p14 and Smad4 shRNAs, the most frequently found alterations in human PDAC. To our knowledge, this is the first study in which a combination of the most common genetic alterations in human PDAC induced a tumorigenic transformation of HPDE, a key difference between this model and other models (22–24). Histologic analysis of the tumors revealed moderately or poorly differentiated PDAC, characteristic of the tumors formed by cultured human PDAC cell lines with desmoplastic stroma in some areas of PDAC. No metastasis was detected in other mouse organs, suggesting that additional genetic or epigenetic changes may be necessary to acquire a
metastasis phenotype. Thus, our model recapitulates human pancreatic carcinogenesis from gene lesion, activation of specific signaling pathway, and some histopathologic features of PDAC.

Recent advancements in human cell culture transformation models have shown the malignant transformation of a variety of normal human cells after the introduction of a limited number of genetic alterations (22–24). The cancer biology of the murine and human is different (16). Malignant transformation is more difficult in human cells than in rodent cells because more genetic alterations are required in human cells than in rodent cells (25). At least 4 to 6 major genetic alterations, including disruption of Rb, p53, and telomerase, mitogenic stimulation such as that associated with Ras, and angiogenesis, are required to transform human cells, which is consistent with the multistep process of PDAC development resulting from the sequential accumulation of genetic lesions in normal cells (26).

One remarkable difference between this model and other models (22–24) is that genetic elements used in this model are the most frequent gene alterations in human PDAC: activation of K-ras and Her2, inactivation of p16/p14 and Smad4. These most common genetic alterations enabled HPDE cells to acquire sustaining proliferative signaling, evade growth suppressors, and finally led to tumorigenic transformation (Fig. 6C). Therefore, this model recapitulates the molecular mechanisms of human pancreatic carcinogenesis better than previous models. However, one weakness of our study is that a single starting cell line, HPDE, was used to generate all of the different cell lines expressing various combinations of PDAC signature alterations. We would also like to point out that HPDE is one of 2 immortalized, nontumorigenic human pancreatic cell lines. Furthermore, it is the only pancreatic ductal epithelial cell line. The other difference involves using E6E7 genes in the immortalization step. p53 inactivation results in dysregulation of 2 critical controls of cell division and cell death and extensive genetic instability, as shown in recent PDAC mouse models for accelerated progression of K-ras–initiated pancreatic neoplasia (27). Because E6 and E7 proteins may perturb other cellular targets in addition to pRB and p53 tumor suppressor, the possibility remains that additional pathways may also be altered in order for tumorigenic transformation to occur.

Our results suggested that expression of K-ras and Her2 and knockdown of p16/p14 and Smad4 are sufficient and essential for tumorigenic transformation of immortalized HPDE cells and that knocking down of Smad4 plays an important role in pancreatic tumorigenesis.

One very interesting and novel finding from our study was that p14shRNA-mediated increase in MDM2 level did not seem to affect p53 stability, as shown in Fig. 5. It is unclear why the increased level of MDM2 failed to enhance p53 degradation (28). p14 binds to MDM2 and inhibits MDM2-mediated proteasome degradation of p53 and inhibited the malignant conversion of these PanIN lesions into PDAC (20, 29). In addition, p14 also has p53-independent functions (30). This feedback regulation loop might be disrupted by E6 oncoprotein-mediated inactivation of p53 in the immortalization step for establishing HPDE cells (Supplementary Fig. S1). To determine the role of p14 in the development of PDAC, we silenced p16INK4a alone and p16INK4a and p14 together.

The other novel finding was that overexpression of Bmi-1, a putative polycomb ring finger oncogene, was found in the tumorigenic HPDE cell line and in most human pancreatic cancer cell lines. We found that inactivation of Smad4 enhanced the expression of Bmi-1, which is a stem cell marker and plays a key role in regulating cell proliferation, self-renewal, senescence, survival, epithelial-to-mesenchymal transition, invasion, and metastasis (31, 32). Overexpression of Bmi-1 was found in human PanIN lesions (33), PDAC cell lines, and patient tissues and has been correlated with lymph node metastasis, patient survival, and poor prognosis (33, 34). Silencing of Bmi-1 reduced proliferation, growth, and survival of PDAC cells; in addition, it inhibited anchorage-independent colony growth in vitro and xenograft tumor growth in vivo in animal models (35). Taken together, these results indicated that inactivation of Smad4 results in dysregulation of Smad4 downstream genes such as Bmi-1, leading to Bmi-1 overexpression, which in turn may contribute to transformation and tumorigenesis of human pancreatic cells.

Our microarray data signaling pathway analysis suggests that the ILK signaling pathway, which regulates a variety of cellular reactions including proliferation, adhesion, migration, differentiation, survival, invasion, and angiogenesis, is highly enriched in the transformed cell lines. Our novel experimental cell transformation model system with genetically defined alterations would provide a necessary tool for studying the molecular mechanism of disease progression by dissecting specific oncogenic signaling pathways in human PDAC.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Z. Chang, Y. Yuan, J. Niu, P.J. Chiao
Development of methodology: Z. Chang, Y. Kang, J. Niu
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Z. Chang, Z. Li, X. Wang, J. Niu, H. Wang, D. Chatterjee, P.J. Chiao
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Z. Chang, Y. Kang, Y. Yuan, H. Wang, D. Chatterjee, P.J. Chiao
Writing, review, and/or revision of the manuscript: Z. Chang, Y. Kang, Y. Yuan, H. Wang, D. Chatterjee, M. Li, J.L. Abbuzzese, P.J. Chiao
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Z. Chang, Y. Yuan, J.B. Fleming, J.L. Abbuzzese

Acknowledgments
The authors thank Dr. Ming-Sound Tsao at the Ontario Cancer Institute/Princess Margaret Hospital, University of Toronto (Toronto, Ontario, Canada) for providing the HPDE cell line, Yu Cao for providing technical support, and Tammy K. Locke for editing the manuscript.
Grant Support

This research was supported in part by the NIH through MD Anderson's Center Cancer Support Grant CA016672 and through grants R01CA097159 and R01CA094005 (to P.J. Chiao).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

References


Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells

Zhe Chang, Zhongkui Li, Xiaoyang Wang, et al.

*Clin Cancer Res*  Published OnlineFirst January 22, 2013.

**Updated version**
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-0032

**Supplementary Material**
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/11/27/1078-0432.CCR-12-0032.DC1

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.